Wedbush initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform rating and $38 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Holds Annual Stockholders Meeting
- Cartesian Therapeutics announces employment inducement grants
- Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections
- Cartesian announces first participant enrolled in Phase 3 AURORA trial
- Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho